[ad_1]
An individual walks by an indication that reads, “the vaccine is our greatest shot in opposition to COVID-19” on the Higher West Aspect amid the coronavirus pandemic on March 30, 2021 in New York Metropolis.
Noam Galai | Getty Photos
Johnson & Johnson privately requested Covid-19 vaccine rivals Pfizer and Moderna to hitch a examine trying into the potential threat of blood clots however the firms declined, The Wall Road Journal reported Friday, citing folks aware of the matter.
Executives at Pfizer and Moderna mentioned their vaccines appeared secure and so they did not see the necessity to duplicate the efforts of regulators and firms already trying into the uncommon blood-clot subject, in keeping with the Journal report.
Solely AstraZeneca, whose vaccine has additionally raised issues from regulators over blood clots, agreed to hitch the hassle, the Journal mentioned.
CNBC has reached out to the 4 firms for remark.
On Tuesday, the Meals and Drug Administration and the Facilities for Illness Management and Prevention suggested states to briefly pause the usage of J&J’s vaccine “out of an abundance of warning” after six ladies developed a uncommon however probably life-threatening blood-clotting dysfunction that left one useless and one in vital situation.
The ladies developed the situation generally known as cerebral venous sinus thrombosis, or CVST, inside about two weeks of receiving the shot, U.S. well being officers advised reporters. CVST is a uncommon type of a stroke that occurs when a blood clot types within the mind’s venous sinuses. It could finally leak blood into the mind tissues and trigger a hemorrhage.
A CDC panel on Wednesday determined to postpone a call on the usage of J&J’s vaccine whereas officers examine the circumstances.
Learn the complete Wall Road Journal report right here.
[ad_2]
Source link